/* 
  Localizable.strings
  CASPe

  Created by Luis Ruiz del Fresno on 12/07/12.
  Copyright (c) 2012 __MyCompanyName__. All rights reserved.
*/

// CLAVE            = Valor que toma en inglés;

"Lectura Crítica"   = "Critical Appraisal";
"Lecturas"          = "Topics";
"Pendiente de Lectura" = "Appraisal pending";

"año/s"             = "year/s";

"bloque 1"          = "In patientes with THIS DISEASE and a %0.0f%% BASAL RISK for developing THIS ADVERSE OUTCOME in %@; "; //RABasal, tiempoSeguimiento.

"bloque 2.1"        = "this experimental treatment for %@ can be BETTER than control treatment: the point stimation of its effect is one outcome less in every %0.0f treated patients (95%% sure treating %0.0f to %0.0f patients). This difference is statistically significant. Now, we have to evaluate wether it is clinically significant too."; //TiempoTt //NNT, nntIC95-SUP, nntIC95-INF"

"bloque 2.2"        = "this experimental treatment for %@ does NOT produce an STATISTICALLY SIGNIFICANT DIFFERENCE compared to control treatment. "; //TratamientoTpo

"bloque 2.3"        = "this experimental treatment for %@ can be WORST than control treatment: the point stimation of its effect is approximately one additional outcome in every %0.0f treated patients (95%% sure treating %0.0f to %0.0f patients). This difference is statistically significant. Now, we have to evaluate wether it is clinically significant too."; //TiempoTto, NNT, INF SUP

"bloque 3.1"        = "Even though the point stimation of its effect is BENEFICIAL, indicating it could avoid in average one outcome in every %0.0f treated patients (perhaps one in every %0.0f treated patients), data are ALSO COMPATIBLE WITH BEING HARMFUL and able to cause in average one additional outcome in every %0.0f treated patients. Now, we have to evaluate its clinical significance.";//NNT, nnt-SUP, nnt-INF

"bloque 3.2"        = "Even though the point stimation of its effect is HARMFUL, indicating it could induce in average one additional outcome in every %0.0f treated patients (perhaps one in every %0.0f treated patients), data are ALSO COMPATIBLE WITH BEING BENEFICIAL and able to avoid in average one outcome in every %0.0f treated patients. Now, we have to evaluate its clinical significance."; //NNT, nnt-INF, nnt-SUP 

"calculadoraNNT"    = "NNT Calculator";
"calculadoraDiag"   = "PostTest Probability Calculator";

"Casos y Controles" = "Case Control Study";
"Cohortes"          = "Cohort Study";
"Ensayo Clínico"    = "Randomized Control Trial";
"Estudios Cualitativos" = "Qulitative Research";
"Evaluación Económica"  = "Economic Evaluations";
"Reglas de Predicción Clínica"  = "Clinical Prediction Rule";
"Revisión"          = "Systematic Review";
"Test Diagnóstico"  = "Diagnostic Test Study";

"De acuerdo"        = "OK";
"día/s"             = "day/s";

"EnlaceACalcNNT"    = "Do you need to calculate NNT?";
"EnlaceACalcDiag"   = "Do you need to calculate Post-Test Pr?";
"espeIC95Label"     = "Sp: %0.0f (%0.0f-%0.0f)";
"EtiquetaRRA"       = "ARR:";

"Interpretación NNT"= "NNT Interpretation";

"mes/es"            = "month/s";

"NNT95LabelSinIC"   = "NNT: %0.1f (%0.0f a %0.0f)";
"NNT95Label"        = "NNT: %0.1f; 95%%CI: %0.1f to %0.1f";
"NNTNeg95Label"     = "NNH: %0.1f; 95%%CI: %0.1f to %0.1f";
"NNTLabel"          = "NNT: %0.0f";
"No"                = "No";
"No sé"             = "Can't tell";
"NoResponde"        = "No answer";

"ResultadosRCTGen"      = "NNT: %0.0f.\nBasal risk: %0.1f%%.\n";
"ResultadosRCTDesdeRiesgos" =  "NNT: %0.0f.\nBasal risk: %0.1f%%.\nARR: %0.1f%%.\n";
"ResultadosRCTDesdeRaw"     = "In the Experimental group %0.0f patients out of %0.0f developed the outcome, vs %0.0f out of %0.0f in the Control group.\nNNT is %0.0f (95%%IC: %0.1f, %0.1f), being the Basal risk %0.1f%%.\n";

"ResultadosDiag"    = "Likelihood ratio: %0.1f.\nIf the PreTest probability were: %0.0f%%.\nPostTest probability would be: %0.0f%%.\n";
"ResultadosDiagSE"  = "Sensitivity: %0.0f%%.\nSpecificity: %0.0f%%.\nLikelihood ratio for %@: %0.1f.\nIf the PreTest probability were: %0.0f%%.\nPostTest probability would be: %0.0f%%.\n";
"ResultadosDiagRaw" = "There were %0.0f positives in %0.0f cases, and %0.0f negatives in %0.0f non-cases.\nIt means Sensitivity: %0.0f%%, Specificity: %0.0f%%.\nLikelihood ratio for %@: %0.1f (95%%IC: %0.1f-%0.1f).\nIf the PreTest probability were: %0.0f%%.\nPostTest probability would be: %0.0f%%.\n";
"ResultadosDiagGen" = "Likelihood ratio: %0.1f.\nIf the PreTest probability were: %0.0f%%.\nPostTest probability would be: %0.0f%%.\n";
"ResultadosDiagGenSE" = "Likelihood ratio for %@: %0.1f.\nIf the PreTest probability were: %0.0f%%.\nPostTest probability would be: %0.0f%%.\n";
"ResultadosDiagGenRaw" = "Likelihood ratio for %@: %0.1f (95%%IC: %0.1f-%0.1f).\nIf the PreTest probability were: %0.0f%%, PostTest probability would be: %0.0f%%.\n";

"Enviar por SMS"    = "To SMS (plain text)";
"Lectura Crítica - www.redcaspe.org" = "Critical Appraisal - www.casp-uk.net";

"Pistas"            = "Hints";
"postLabelVacia"    = "Post-Test Pr:";
"postLabel"         = "Post-Test Pr: %0.0f %%";
"PreTestLabel"      = "Pre-Test Pr: %0.0f %%";

"RBasalEtiqueta"    = "BASAL R";
"reducRiesgoAbs95LabelVacia" = "Absolute Risk Reduction (95%CI):";
"reducRiesgoAbsLabelVacia" = "Absolute Risk Reduction:";
"redRisrelLabVacia" = "RRR:";
"riesgoBasalLabel"  = "Con R: %0.0f%%";
"riesgoBasalLabelSmall" = "Con R: %0.1f%%";
"riesgoConLabelVacia" = "Con Abs Risk:";
"riesgoExpLabel"    = "Exp R: %0.0f%%";
"riesgoExpLabelSmall" = "Exp R: %0.1f%%";

"riesgoExpLabelVacia" = "Exp Abs Risk:";
"riesgoRelaLabel" = "Relative Risk: %0.1f";
"riesgoRelLabelVacia" = "Relative Risk:";
"RRA95Label"        = "Absolute Risk R: %0.0f%% (%0.1f to %0.1f)";
"RRA95LabelSmall"        = "Absolute Risk R: %0.1f%% (%0.1f to %0.1f)";

"RRALabel"          = "Absolute Risk R: %0.0f%%";
"RRRLabel"          = "RRR %0.1f";
"rv95LabelT+"       = "LR (positive): %0.1f (95%%CI: %0.1f-%0.1f)"; 
"rv95LabelT-"       = "LR (negative): %0.2f (95%%CI: %0.2f-%0.2f)";
"rv95LabelVacia"    = "Likelihood Ratio (95%CI):";
"rvCalcLabel+"      = "Likelihood Ratio (positive): %0.1f";
"rvCalcLabel-"      = "Likelihood Ratio (negative): %0.1f";
"rvCalcLabel"       = "Likelihood Ratio:";

"Referencia"        = "Reference";
"Título"            = "Issue";
"Revista"           = "Journal";
"PubMedID"          = "PubMedID";

"PubMedID"          = "PubMedID";
"Lectura Crítica"   = "Critical Appraisal";
"Comentarios"       = "Comments";
"Revisor"           = "Reviewer";
"Nombre"            = "Name";
"Correo"            = "E-Mail";
"Fecha"             = "Date";
"Etiquetas"         = "Tags";
"Escriba aquí el Título" = "Write here a short title";
"Escriba aquí la Revista" = "Write here the article citation or if you know its PubMedID or DOI touch on the left side of this row to import it from PubMed";
"Escriba aquí el PubMedID" = "Input PubMedID/DOI here to import";
"Escriba aquí sus comentarios" = "Write here your comments";
"EtiquetaIndicePorDefecto" = "Unindexed";

"NoSeEncuentraPorDoi" = "Not found by doi, try with PubMedID";

"comentarios"       = "Comments:";

"InfoCASP"          = "CASP Information";

"Recuerde"          = "Remenber";

"Autor no detectado"   = "No Author detected";
"Titulo no detectado" = "No Title detected";
"Revista no detectada" = "No Journal detected";

"TituloPubMedAlertView" = "To import a reference from PubMed: input PubMedID and choose PubMed.";
"Desde PubMed"      = "PubMed";
"Manualmente"       = "Cancel";

"Cita"              = "Appraisal";
"Previo"            = "Previous";
"Siguiente"         = "Next";
"Creando una L Crítica Nueva" = "Creating a new appraisal";
"Cancelar"          = "Cancel";
"Fecha"             = "Date";
"Copia modificable" = "Do an editable copy";
"Enviar por correo" = "To E-Mail (CASP+PDF)";
"Borrar esta Lectura" = "Delete this Appraisal";
"¿Quiere borrar está lectura?" = "Do you want to delete this appraisal?";
"Pulsando Sí la borrará de forma definitiva" = "Selecting Yes, it will be permanently deleted";
"Una Lectura Crítica" = "A Critical Appraisal";
"¡Revise esta Lectura Crítica! Necesitará tener instalada CASP, luego pulse en el icono para abrirla." = "Check out this Critical Appraisal!  You'll need a copy of CASP to view this file, then tap and hold to open.";
"Escriba una etiqueta nueva" = "Write a new tag";
"Seleccione las que desee" = "Select what you want";
"Editar"            = "Edit";

"pista"             = "Hint:";

"NNT %0.0f (IC95%%: %0.0f a %0.0f)" = "NNT %0.0f (95%%CI: %0.0f to %0.0f)";

"Pulse aquí para crear una lectura crítica" = "Tap here to create a Critical Appraisal";
"Modificar Etiquetas" = "Edit Tags";
"Esta reseña NO tiene una Lectura Crítica" = "This reference hasn't got a Critical Appraisal";
"¿Quiere hacerla ahora?" = "Are you going to create it now?";
"No"                = "No";
"Sí"                = "Yes";
"SíEnRespuestas"    = "Yes / Good";
"NoEnRespuestas"    = "No / Poor";

"TituloActionSheetAcciones" = "What do you wish to do with this Appraisal?";
"Guardar como PDF"  = "Export to PDF";

"Lectura %@"        = "Critical Appraisal: %@";

"Page %d"           = "Page %d";

"Índice"            = "Index";

"Esta reseña YA tiene una Lectura Crítica previa" = "Already exists a Critical Appraisal for this reference";
"¿Quiere modificar la existente o duplicar la lectura para conservar 2 versiones?" = "Do you want to edit it, or to duplicate it and keep the old and new versions?";
"Modificar"         = "Edit";
"Duplicar"          = "Duplicate";
"Revisor por Defecto" = "Default Reviewer";
"Si quiere modificar sus datos, puede hacerlo en Ajustes" = "If you want to modify reviewer's data, you can do it in Settings";
"De acuerdo"        = "Ok";
"Ok"                = "Done"; //Es el texto de un botón en el menú etiquetas

"Copiar los Resultados en Comentarios" = "Copy Results in Comments";
"El test"           = "This test";
"El test positivo"  = "A positive result";
"El test negativo"  = "A negative result";
", potente."        = ", strong.";
" %@ tiene una Razón de Veromilitud de %0.1f%@ Con una probabilidad PreTest de %0.0f%% la probabilidad PostTest sería %0.0f%%"  = " %@ has a likelihood ratio of %0.1f%@ When PreTest probability is %0.0f%% PostTest probability goes to %0.0f%%";

"Seguimnt"          = "FollowUp";
"semana/s"          = "week/s";
"senIC95Label"      = "Sn: %0.0f (%0.0f-%0.0f)";
"SenEspValidValues" = "Sensitivity and Specificity only admit values between 0 and 100";

"tituloCalcNNT"     = "NNT";
"tituloCalculadoras"= "Calculators";
"titleDiagVC"       = "Post-Test Probability";
"TituloInfoVC"      = "About CASP"; 
"TituloGlosarioVC"  = "Glossary";
"TituloPlantillaVC" = "Checklists";
"Tratamnt"          = "Treatmnt";

"ValorNoValido"     = "Invalid Input";
"ValorValido"       = "Absolute risks only admit values between 0 and 100";

"No especificado" = "Not specified";

//Respecto a la interpretación escrita del intervalo de confianza del NNT, sigue el siguiente esquema
/*
 
 A              En pacientes con esta enfermedad y un riesgo basal de desarrollar este desenlace adverso del %0.1f %% en %@. El uso de A   
                (en vez de B), durante %@	
    
                In patients with this disease, and %0.1f  basal risk to develop this outcome. Use of treatment A (instead of B), for %@”
 
 B1: Si RRA/NNT estimado es positivo	
                podría ser BENEFICIOSO, evitaría en promedio 1 desenlace adverso por cada %0.0f pacientes tratados	
 
                could be BENEFICIAL, avoiding in average 1 adverse outcome for every &0.0f patients treated
 
 B11 (resultado pos y significativo)	
                (IC95%%: %0.0f a %0.0f [cuanto mayor es el valor de NNT más pequeño es el beneficio]). Esta diferencia es estadísticamente significativa.	
            
                (95%%CI: %0.0f to %0.0f [the bigger the NNT value, the smaller the benefice]).  This difference is statistically significant.
 
 B12 (resultado pos pero no significativo)	
                , pero esta diferencia NO es estadísticamente significativa (IC95%%: %0.0f a %0.0f), ya que el IC95%% es compatible con que A fuese ineficaz o incluso perjudicial. Concretamente IC95%% va desde que A produjese un desenlace perjudicial adicional tratando entre %0.0f e infinitos pacientes, hasta que evitase un desenlace tratando entre infinitos y %0.0f pacientes (IC95%%: perjudicial con %0.0f a inifinitos, hasta beneficioso con infinitos a %0.0f, ver gráfico).	
            
                , but this differenece is NOT statistically significant (95%%CI: %0.0f to %0.0f), because 95%%CI is compatible with A be ineffective or even harmful. Specifically this 95%%CI is compatible with all results between inducing 1 additional adverse outcome for every %0.0f or more patients treated in the harmful end, and avoiding 1 adverse outcome for every %0.0f or more patients treated in the beneficial end (in other words: 95%%CI: harmful treating from %0.0f to infinite, and beneficial treating from infinite to %0.0f patients, see “graphic interpretation”).
 
 B2 (resultado negativo)	
                podría ser PERJUDICIAL, produciría en promedio 1 desenlace adverso por cada %0.0f pacientes tratados	
 
                could be HARMFUL, inducing in average 1 additional adverse outcome for every %0.0f patients treated
 
 B21 (result negativo y signi)	
                (IC95%%: %0.0f a %0.0f). Esta diferencia es estadísticamente significativa.	
 
                (95%%CI: %0.0f to %0.0f). This difference is statistically significant.
 
 B22 (resul negativo pero No signi)	es igual a B12.
                , pero esta diferencia NO es estadísticamente significativa (IC95%%: %0.0f a %0.0f), ya que el IC95%% es compatible con que A fuese ineficaz o  beneficioso. Concretamente IC95%% va desde que A produjese un desenlace perjudicial adicional tratando entre %0.0f e infinitos pacientes, hasta que evitase un desenlace tratando entre infinitos y %0.0f pacientes (IC95%%: perjudicial con %0.0f a inifinitos, hasta beneficioso con infinitos a %0.0f, ver gráfico).	
 
                , but this differenece is NOT statistically significant (95%%CI: %0.0f to %0.0f), because 95%%CI is compatible with A be ineffective or even harmful. Specifically this 95%%CI is compatible with all results between inducing 1 additional adverse outcome for every %0.0f or more patients treated in the harmful end, and avoiding 1 adverse outcome for every %0.0f or more patients treated in the beneficial end (in other words: 95%%CI: harmful treating from %0.0f to infinite, and beneficial treating from infinite to %0.0f patients, see “graphic interpretation”).
*/
